Literature DB >> 19917269

Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor.

John A Auchampach1, Elizabeth T Gizewski, Tina C Wan, Sonia de Castro, Garth G Brown, Kenneth A Jacobson.   

Abstract

A recently reported selective agonist of the human A(3) adenosine receptor (hA(3)AR), MRS5127 (1'R,2'R,3'S,4'R,5'S)-4'-[2-chloro-6-(3-iodobenzylamino)-purine]-2',3'-O-dihydroxy-bicyclo-[3.1.0]hexane, was radioiodinated and characterized pharmacologically. It contains a rigid bicyclic ring system in place of a 5'-truncated ribose moiety, and was selected for radiolabeling due to its nanomolar binding affinity at both human and rat A(3)ARs. The radioiodination of the N(6)-3-iodobenzyl substituent by iododestannylation of a 3-(trimethylstannyl)benzyl precursor was achieved in 73% yield, measured after purification by HPLC. [(125)I]MRS5127 bound to the human A(3)AR expressed in membranes of stably transfected HEK 293 cells. Specific binding was saturable, competitive, and followed a one-site binding model, with a K(d) value of 5.74+/-0.97nM. At a concentration equivalent to its K(d), non-specific binding comprised 27+/-2% of total binding. In kinetic studies, [(125)I]MRS5127 rapidly associated with the hA(3)AR (t(1/2)=0.514+/-0.014min), and the affinity calculated from association and dissociation rate constants was 3.50+/-1.46nM. The pharmacological profile of ligands in competition experiments with [(125)I]MRS5127 was consistent with the known structure-activity-relationship profile of the hA(3)AR. [(125)I]MRS5127 bound with similar high affinity (K(d), nM) to recombinant A(3)ARs from mouse (4.90+/-0.77), rabbit (2.53+/-0.11), and dog (3.35+/-0.54). For all of the species tested, MRS5127 exhibited A(3)AR agonist activity based on negative coupling to cAMP production. Thus, [(125)I]MRS5127 represents a new species-independent agonist radioligand for the A(3)AR. The major advantage of [(125)I]MRS5127 compared with previously used A(3)AR radioligands is its high affinity, low degree of non-specific binding, and improved A(3)AR selectivity. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917269      PMCID: PMC2815200          DOI: 10.1016/j.bcp.2009.11.009

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  34 in total

1.  Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium.

Authors:  Y Kohno; X Ji; S D Mawhorter; M Koshiba; K A Jacobson
Journal:  Blood       Date:  1996-11-01       Impact factor: 22.113

2.  Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands.

Authors:  Susanna Tchilibon; Soo-Kyung Kim; Zhan-Guo Gao; Brian A Harris; Joshua B Blaustein; Ariel S Gross; Heng T Duong; Neli Melman; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2004-05-01       Impact factor: 3.641

Review 3.  Medicinal chemistry of adenosine A3 receptor ligands.

Authors:  Christa E Müller
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

4.  The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition.

Authors:  Lea Madi; Avivit Ochaion; Lea Rath-Wolfson; Sara Bar-Yehuda; Abigail Erlanger; Gil Ohana; Arie Harish; Ofer Merimski; Faina Barer; Pnina Fishman
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

5.  Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position.

Authors:  Michihiro Ohno; Zhan-Guo Gao; Philippe Van Rompaey; Susanna Tchilibon; Soo-Kyung Kim; Brian A Harris; Ariel S Gross; Heng T Duong; Serge Van Calenbergh; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2004-06-01       Impact factor: 3.641

6.  The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways.

Authors:  S Bar-Yehuda; S M Stemmer; L Madi; D Castel; A Ochaion; S Cohen; F Barer; A Zabutti; G Perez-Liz; L Del Valle; P Fishman
Journal:  Int J Oncol       Date:  2008-08       Impact factor: 5.650

7.  Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.

Authors:  Artem Melman; Ben Wang; Bhalchandra V Joshi; Zhan-Guo Gao; Sonia de Castro; Cara L Heller; Soo-Kyung Kim; Lak Shin Jeong; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2008-08-07       Impact factor: 3.641

8.  Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype.

Authors:  Stefania Gessi; Stefania Merighi; Katia Varani; Elena Cattabriga; Annalisa Benini; Prisco Mirandola; Edward Leung; Stephen Mac Lennan; Carlo Feo; Stefania Baraldi; Pier Andrea Borea
Journal:  J Cell Physiol       Date:  2007-06       Impact factor: 6.384

9.  Preparation and first evaluation of [(18)F]FE@SUPPY: a new PET tracer for the adenosine A(3) receptor.

Authors:  Wolfgang Wadsak; Leonhard-Key Mien; Karem Shanab; Dagmar E Ettlinger; Daniela Haeusler; Karoline Sindelar; Rupert R Lanzenberger; Helmut Spreitzer; Helmut Viernstein; Bernhard K Keppler; Robert Dudczak; Kurt Kletter; Markus Mitterhauser
Journal:  Nucl Med Biol       Date:  2008-01       Impact factor: 2.408

10.  N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors.

Authors:  Zhan-Guo Gao; Joshua B Blaustein; Ariel S Gross; Neli Melman; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2003-05-15       Impact factor: 5.858

View more
  13 in total

Review 1.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

2.  Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions.

Authors:  Dilip K Tosh; Silvia Paoletta; Khai Phan; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  ACS Med Chem Lett       Date:  2012-06-11       Impact factor: 4.345

3.  Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A3 Adenosine Receptors: Affinity Enhancement by N6-(2-Phenylethyl) Substitution.

Authors:  Dilip K Tosh; Veronica Salmaso; Harsha Rao; Amelia Bitant; Courtney L Fisher; David I Lieberman; Helmut Vorbrüggen; Marc L Reitman; Oksana Gavrilova; Zhan-Guo Gao; John A Auchampach; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2020-04-09       Impact factor: 7.446

4.  A binding kinetics study of human adenosine A3 receptor agonists.

Authors:  Lizi Xia; Athina Kyrizaki; Dilip K Tosh; Tirsa T van Duijl; Jacomina Cornelia Roorda; Kenneth A Jacobson; Adriaan P IJzerman; Laura H Heitman
Journal:  Biochem Pharmacol       Date:  2018-01-03       Impact factor: 5.858

5.  A role for the low-affinity A2B adenosine receptor in regulating superoxide generation by murine neutrophils.

Authors:  Dharini van der Hoeven; Tina C Wan; Elizabeth T Gizewski; Laura M Kreckler; Jason E Maas; Jordan Van Orman; Katya Ravid; John A Auchampach
Journal:  J Pharmacol Exp Ther       Date:  2011-06-21       Impact factor: 4.030

6.  Click modification in the N6 region of A3 adenosine receptor-selective carbocyclic nucleosides for dendrimeric tethering that preserves pharmacophore recognition.

Authors:  Dilip K Tosh; Khai Phan; Francesca Deflorian; Qiang Wei; Lena S Yoo; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2012-01-11       Impact factor: 4.774

7.  A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity.

Authors:  Dilip K Tosh; Veronica Salmaso; Ryan G Campbell; Harsha Rao; Amelia Bitant; Eline Pottie; Christophe P Stove; Naili Liu; Oksana Gavrilova; Zhan-Guo Gao; John A Auchampach; Kenneth A Jacobson
Journal:  Eur J Med Chem       Date:  2021-11-19       Impact factor: 6.514

8.  Probing structure-activity relationship in β-arrestin2 recruitment of diversely substituted adenosine derivatives.

Authors:  Jolien Storme; Dilip K Tosh; Zhan-Guo Gao; Kenneth A Jacobson; Christophe P Stove
Journal:  Biochem Pharmacol       Date:  2018-10-04       Impact factor: 5.858

9.  Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain.

Authors:  Silvia Paoletta; Dilip K Tosh; Amanda Finley; Elizabeth T Gizewski; Steven M Moss; Zhan-Guo Gao; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2013-07-03       Impact factor: 7.446

10.  Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts.

Authors:  Tina C Wan; Dilip K Tosh; Lili Du; Elizabeth T Gizewski; Kenneth A Jacobson; John A Auchampach
Journal:  BMC Pharmacol       Date:  2011-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.